[Edaily Reporter Park Jung-Soo ] #Rznomics Inc., a company specializing in the development of RNA-based gene therapies, announced on the 24th that it will move into “Lilly Gateway Labs” in San Diego, U.S.
Lilly Gateway Labs is an innovation hub that supports the research and development of biotech companies by providing wet lab facilities and opportunities to interact with Lilly researchers and executives.
Lilly Gateway Labs, together with Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, forms “Lilly Catalyze360.” Through this initiative, Lilly provides biotech companies with strategic capital, research space, technology, and R&D capabilities.
Rznomics Inc. plans to use this move as an opportunity to accelerate the development of therapeutic candidates by leveraging its gene bank of more than 200 target diseases.
In the long term, the company intends to establish a global clinical infrastructure for its core pipeline, expand global partnerships, and recruit specialized research personnel in the U.S.
Lee Seong-wook, CEO of Rznomics Inc., stated, “Joining the bio-cluster led by Eli Lilly is a significant milestone for Rznomics Inc.’s proprietary RNA platform,” adding, “We will advance the development and commercialization of RNA therapeutics by leveraging active collaboration with the global biotech ecosystem.”